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Abstract
Purpose Clevidipine is a rapidly-acting intravenous dihydro-
pyridine antihypertensive acting via calcium channel block-
ade. This was a randomized, single-blind, parallel-design
study of a 72-h continuous clevidipine infusion.
Method Doses of 2, 4, 8, or 16.0 mg/h or placebo were
evaluated in 61 subjects with mild to moderate essential
hypertension. IV clevidipine or placebo was initiated at
2.0 mg/h and force-titrated in doubling increments every
3 min to target dose, then maintained for 72 h. Blood pressure
and heart rate were measured during infusion, and for 4, 6 and
8 h after termination of infusion, although oral therapy could
be restarted at 4 h. Clevidipine blood levels were obtained
during infusion and for 1 hour after termination.
Results Rapid onset of drug effect occurred at all clevidi-
pine dose levels, with consistent pharmacokinetics and rapid
offset after 72-h infusion. No evidence of tolerance to the
clevidipine drug effect was observed at any dose level over the
72-h infusion. No evidence of rebound hypertensionwas found
for either 4 or 6 h after termination of the clevidipine infusion.
At 8 h following cessation of clevidipine, blood pressure was
not significantly higher than at baseline. Placebo-treated sub-
jects had blood pressures lower than baseline at 8 h following
infusion termination; hence, placebo-adjusted blood pressures
tended to be slightly higher than baseline.
Conclusion This study supports the use of up to 72 h of IV
clevidipine therapy for the management of blood pressure,
with consistent pharmacokinetic/pharmacodynamic charac-
teristics and context insensitive half-life across the dose
ranges evaluated.
Keywords Clevidipine . Hypertension . Blood pressure .
Antihypertensive . Intravenous . Calcium channel
blocker . 1,4-dihydropyridine . Pharmacokinetics .
Pharmacodynamics
Introduction
Subjects with acute, severe hypertension require intravenous
(IV) therapy when rapid, controlled blood pressure (BP)
reduction is necessary and the administration of oral agents
is not feasible [1, 2]. The ideal therapeutic profile for an IV
antihypertensive agent would include rapid action, predict-
ability, easy titratability, short duration after discontinuation,
and minimal risk of unwanted drug effects [2–5].
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Clevidipine, the latest-generation dihydropyridine calci-
um channel blocker, lowers BP through arterial-specific
peripheral vasodilation without adverse myocardial effects.
Owing to its direct effect activity and ultra-short half-life,
clevidipine has a rapid onset and offset of effect allowing
precise titration to target BP levels and maintenance of tight
control over time [6–8]. Following administration, clevidipine
exhibits triphasic elimination with the initial phase accounting
for the majority (approximately 85–90 %) of the area under the
concentration–time curve [8–10]. Metabolism is achieved by
the action of esterases in the blood and extravascular tissues,
resulting in an initial half-life of approximately 1 min [8–10].
There is limited clinical experience with prolonged (>24 h)
continuous infusion of clevidipine. This study evaluated the
pharmacokinetics (PK), pharmacodynamics (PD), and safety
of continuous clevidipine infusion, including the potential for
tolerance during treatment and for rebound hypertension upon




The study was conducted using a randomized, single-blind,
placebo-controlled, parallel-group design. There were three
study phases: screening/run-in for up to 14 days (Study Days
−14 to −1), treatment for 72 h (Days 1–3) and follow-up for
4 days (Days 4–7), for a maximum of 21 days. All eligible
subjects were confined to the clinic at least 12 h before
treatment. Subjects were randomized to one of four dosing
cohorts for continuous treatment over 72 h with clevidipine or
placebo. The study was approved by the Institutional Review
Board at each study site, and was conducted in compliance
with the International Conference on Harmonization (ICH)
Good Clinical Practice (GCP) guidelines, and with the Dec-
laration of Helsinki. Written informed consent was obtained
from all subjects before the initiation of any study-related
procedures.
Subjects and inclusion/exclusion criteria
Men or women aged 18–80 years with a history of mild to
moderate essential hypertension (treated or untreated) were
screened. Subjects with treated hypertension were required to
withdraw fromoral antihypertensivemedications for 8–14 days
prior to clevidipine administration, and to be off all antihyper-
tensive medication for 7 days prior to study drug administra-
tion. To be eligible for study inclusion, subjects had to be
assessed in the untreated state with systolic blood pressure
(SBP) ≥140 mmHg and <200 mmHg and/or diastolic blood
pressure (DBP) ≥95 mmHg and <115 mmHg, and heart rate
(HR) <120 beats per minute (bpm), as described in the next
section. Additional inclusion criteria included clinical labora-
tory test results within normal limits or with clinically insig-
nificant abnormalities, negative illicit drug and alcohol
screening tests, and if appropriate, negative urine pregnancy
test, documented bilateral oophorectomy and/or hysterectomy,
or postmenopausal status with cessation of menstruation for
>2 years. Exclusion criteria included treatment with ≥5 oral
antihypertensive agents, secondary hypertension, myocardial
infarction or cerebrovascular event within 6 months, conges-
tive heart failure or other severe cardiovascular disease, prior
cerebral hemorrhage or intracranial tumor, liver failure or
cirrhosis, intolerance to calcium channel blockers, allergy to
soybean oil or egg lecithin, or any other condition warranting
exclusion from the study per clinical judgment. Subjects un-
willing to refrain from smoking, caffeine and alcohol and those
involved in another study within 30 days were also excluded.
Assessment for study eligibility based on BP and HR
inclusion criteria
For subjects with untreated hypertension, BP and HR were
obtained two or more times and at least 30 min apart on three
separate days during the screening/run-in period. Subjects had
to rest supine for at least 5 min before assessment. For study
eligibility, on each occasion the average of the two BP meas-
urements had to meet the inclusion criteria for SBP and/or
DBP defined in the previous section, and HR had to be
<120 bpm at every assessment. If the average SBP and/or
DBP was above the upper limit of the inclusion criteria, the
subject was withdrawn from the study and an appropriate
antihypertensive regimen was established under the guidance
of the primary care physician or physician investigator.
Subjects with treated hypertension discontinued their oral
antihypertensive medications during the run-in period in the
reverse order in which they had been prescribed, or, if the
order was unknown, according to clinical judgment. During
this period, BP and HR were monitored at clinic visits every
2–3 days, with measurements obtained after a minimum of
5 min supine rest. If SBP or DBP was above the upper limit of
the infusion criteria at any clinic visit during screening, the
same action was taken as described for untreated subjects.
During the 7-day period when subjects were off all antihyper-
tensive medication prior to study drug administration, subjects
visited the clinic at least every 2–3 days. At each visit, BP and
HR were obtained two or more times and at least 30 min apart
after a minimum of 5 min supine rest per assessment. To be
eligible for the study, each subject had to have three or more
consecutive average SBP and DBP measurements on separate
days that met the inclusion criteria defined in the previous
section, including one average from assessments carried out
on Day −1. Additionally, HR had to be <120 bpm at every
assessment.
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Randomization and blinding
Eligible study subjects were allocated to one of four dosing
cohorts and randomized to clevidipine or placebo within each
cohort. It was planned that within each dosing cohort, 10
subjects would receive clevidipine and 3 would receive pla-
cebo. Subjects were replaced if necessary to ensure that at
least 10 clevidipine-treated and 3 placebo-treated subjects per
dosing cohort completed the study. Study drug infusions
(clevidipine or placebo) were identical in appearance; to
maintain the single blind, labels were covered while infusions
were administered.
Study treatment
Subjects were treated with IV clevidipine (0.5 mg/mL in 20%
lipid emulsion) or with placebo (Intralipid® 20 % IV fat
emulsion) in one of four dosing cohorts defined by clevidipine
target doses of 2.0 mg/h, 4.0 mg/h, 8.0 mg/h, or 16.0 mg/h.
Clevidipine was administered at an initial infusion rate of
2.0 mg/h to subjects in each cohort and force-titrated in
doubling increments every 3 min to the target dose, as appro-
priate. Placebo was administered at the same rate as the
corresponding dose of clevidipine. Clevidipine or placebo
infusions were continued for 72 h once the final infusion rate
had been achieved. Blood pressure changes were monitored
using an automated sphygmomanometer.
Concomitant medications permitted during the run-in,
treatment, and follow-up periods included non-prescription
pain medications (without stimulants) used as per the pack-
age instructions and oral contraceptives; and during treat-
ment and follow-up only, oral lorazepam 10 mg not
exceeding once every 24 h at bedtime. Non-study drug
medications and treatment procedures affecting BP were
prohibited for 7 days prior to study drug administration,
the treatment period, and 4 h following termination of study
drug infusion. If alternative antihypertensive medication
was required, the subject was withdrawn from the study.
All subjects could withdraw from the study at any time. All
subjects could be withdrawn by the study physician at any
time. Any subject withdrawn because of tachycardia or hypo-
tension was to have study drug infusion down-titrated in
halving increments prior to discontinuation. Any subject with-
drawn due to hypertension was to have study drug infusion
maintained during transition to oral antihypertensive(s). If
withdrawn for safety concerns, subjects had vital signs mon-
itored until vital signs were stable for at least 30 min.
Study endpoints
The primary endpoint of the study was mean percentage
change in SBP from baseline over the 72-h treatment period.
Secondary study endpoints were mean percentage change in
SBP from baseline over the first 4 h post-study drug infusion;
clevidipine blood concentration over the 72-h treatment peri-
od through 60 min post-study drug infusion; the relationship
between the time-matched, placebo-adjusted mean percentage
change in SBP from baseline, and the mean blood concentra-
tion of clevidipine over the 72-h treatment period through
60 min post-study drug infusion; and the safety of prolonged
(72 h) clevidipine infusion assessed according to clinical
laboratory parameters, HR, electrocardiography (ECG), ad-
verse events (AEs), and clinical evaluation.
Pharmacodynamic assessments
During the treatment period, BP and HR were obtained pre-
dose, then every 3 min during the titration phase to coincide
with dose changes. After the target dose was reached, BP and
HR were obtained at 5, 10, and 15 min and at 0.5, 2, 4, 8, 12,
16, 24, 30, 36, 42, 48, 54, 60, 66, and 72 h. After study drug
termination, BP and HRwere obtained at 2, 4, 6, 8, 12, 20, 30,
and 60 min; then every 15 min for the next 3 h; then at 6 and
8 h. Subjects could resume their oral BP medication(s) 4 h
after study drug termination in the order previously pre-
scribed, or had an appropriate antihypertensive regimen estab-
lished under physician guidance. On Day 7, BP and HR were
measured to ensure that BP had returned to its pre-study
baseline and had stabilized. If it had not stabilized, the subject
was referred to his or her primary physician or had medica-
tions adjusted by the physician investigator. On all occasions,
BP and HR were obtained after the subject had rested supine
for at least 5 min. The BP cuff was not placed on the arm
receiving study drug infusion. When BP and HR were sched-
uled to be obtained at the same time as a blood sample, the
blood sample was drawn at the scheduled time point and BP
and HR were assessed as soon as possible afterwards.
The dose–response relationship between percentage
change from baseline in SBP and clevidipine infusion rate
(mg/h) was also assessed, using the percentage change in
SBP from baseline to the first SBP measurement after an
increase in infusion rate (but before the next dose rate
change) as the response value to the actual infusion rate.
Dose response was summarized using a random coeffi-
cient regression model, including intercept, slope, and ad-
justment for nonlinearity (square of infusion rate). The
variance–covariance matrix of random effects was assumed
to be unstructured. To eliminate the issue of co-linearity
between slope and nonlinearity, the clevidipine infusion rate
was standardized by subtracting the overall mean infusion
rate prior to fitting the random coefficient regression model.
Pharmacokinetic assessments
Blood samples for determining clevidipine blood concen-
trations were collected pre-dose and 0.5, 2, 4, 8, 12, 16, 24,
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30, 36, 42, 48, 54, 60, 66, and 72 h following achievement
of the target dose. Blood samples were also collected at 2, 4,
6, 8, 12, 20, 30, and 60 min after infusion cessation.
Samples were analyzed for concentration of clevidipine by
liquid chromatography/mass spectrometry/mass spectrometry
(LC/MS/MS) assay (Frontage Laboratories, Inc, Malvern, PA,
USA); the lower limit of quantification was set at 0.2 ng/mL
with an accuracy of 112 % and precision ( %CV) of 7.8 %.
The calibration curves were linear in the range 0.20 to 500 ng/
mL. Blood samples were not analyzed for placebo-treated
subjects. Blood concentration–time data for clevidipine were
analyzed by noncompartmental analysis using the software
program WinNonlin® Professional version 5.0.1 (Pharsight®
Corporation, Mountain View, CA, USA). Actual sampling
times and actual total dose (mg) were used in the calculation
of noncompartmental PK parameters.
Cmax was obtained by visual inspection of the concentra-
tion–time profiles and is the highest observed value that was
obtained. When feasible, Css was calculated by averaging
the last four blood concentrations of clevidipine during the
end phase of the infusion (average of the 54-, 60-, 66- and
72-h time points). AUC0-t was estimated by a combination
of linear trapezoidal methods on increasing concentrations
and logarithmic trapezoidal methods on decreasing concen-
trations. The 73-h concentration value was set as “t” for this
AUC0–t calculation.
When feasible, λz was determined using unweighted linear
regression analysis on at least three log-transformed concen-
trations visually assessed to be on the linear portion of the
terminal slope, but not including the peak concentration. In
general, objective selection of points included in the estimation
of half-life required selection of those points that maximized
R2 for the linear regression. The last measurable concentration
was always included, unless the terminal data point appeared
to be part of a new phase, or there was reason to believe that the
last concentration was in error. When feasible, t½ was calcu-
lated as the ratio of loge2 to λz (t½00.693/λz).
Safety assessments
Non-serious AEs were assessed and recorded from study
drug initiation up to 8 h following study drug termination.
Serious AEs were assessed from screening/run-in to Day 7
of the follow-up period. Blood samples were collected (after
the subjects had fasted for at least 8 h) at screening, Day 4
and Day 7 for blood chemistry, hematology, and lipid panel
tests. A 12-lead ECG was performed at each clinic visit
during the screening/run-in period, then daily until dis-
charge from the clinical research unit and at the Day 7
follow-up visit. A medical history was obtained during the
screening/run-in period, and a physical examination was
performed at the screening/run-in period and upon study
check-in (Day −1).
Statistical analysis
The planned sample size of 52 subjects was judged to be
adequate for this PK/PD study without formal power calcu-
lation. The safety population was defined by protocol as all
subjects who were dosed with any study drug. The per-
protocol (PP) population was defined as all subjects who
received 72 h of continuous treatment at the target dose and
had blood samples for PK analysis obtained with correct
methodology, and was designated as the primary population
for BP, PK, and PD analyses, to allow analysis of data
unaffected by incorrect blood sampling. Additionally, for
better assessment of randomness, the intent-to-treat (ITT)
population was defined as all randomized subjects.
In addition to analysis of pre-specified study endpoints,
post-hoc analyses were performed. In order to more com-
pletely evaluate the potential for rebound hypertension over
a longer period, mean percentage change in SBP and in
DBP from baseline and placebo-corrected changes with
respect to baseline were evaluated at 6 and 8 h following
the cessation of study drug infusion. Descriptive statistics
and graphs were used to summarize study data according to
clevidipine dose level (2.0, 4.0, 8.0, 16.0 mg/h), and place-
bo; data from all placebo-treated subjects allocated to the
four dosing cohorts were pooled.
The ECG parameters included ventricular HR, PR, QTS,
and QT intervals. Laboratory parameters measured from
different local laboratories, including blood hematology,
serum chemistry, and lipid panels, were converted to con-
ventional units and normalized to a standard set of reference
ranges [11–13]. Change from baseline for each of the ECG




Sixty-one hypertensive subjects were enrolled in the study,
and received either clevidipine (n048) or placebo (n013),
and comprise the ITT and Safety populations. Sixty subjects
completed the study: one subject withdrew consent. The Per
Protocol population (n053) consists of 40 clevidipine-
treated subjects (7 subjects whose blood samples were
drawn incorrectly and one subject who withdrew are ex-
cluded) and 13 placebo-treated subjects.
Subject characteristics
Screening demographics and other baseline characteristics
are summarized in Table 1. Subject medical history included
co-morbidities common to this population.
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No meaningful differences in oral antihypertensive regi-
mens between cohorts were observed prior to the study start
and following termination of study drug infusion.
Pharmacodynamic evaluation
All clevidipine dosing cohorts showed a larger percentage
decrease in SBP from baseline compared with placebo
(Fig. 1). The mean percentage change in SBP from baseline
for the 4.0 mg/h, 8.0 mg/h, and 16.0 mg/h cohorts was dose-
proportional. The 2.0 mg/h cohort showed a larger percentage
decrease in SBP from baseline than the 4.0 mg/h cohort. A
rapid onset of drug effect was observed for all clevidipine
cohorts, with no evidence of a diminishing drug effect through-
out the treatment period. From the end of infusion to 4 h post-
infusion there was a rapid return to baseline SBP with no
Table 1 Screening demographics and other baseline characteristics (ITT population)
Parameter Placebo Clevidipine Clevidipine Clevidipine Clevidipine P value
2.0 mg/h 4.0 mg/h 8.0 mg/h 16.0 mg/h
n013 n010 n010 n018 n010
Mean age (SD), years 55 (12.6) 56 (15.3) 47 (11.2) 52 (12.8) 56 (10.4) 0.3866
Mean weight (SD), kg 88.1 (18.95) 87.4 (25.11) 105.3 (17.51) 93.6 (18.18) 99.9 (19.33) 0.1814
Mean BMI (SD), kg/m2 32.1 (5.64) 30.2 (4.43) 34.3 (5.85) 30.6 (5.52) 34.4 (7.05) 0.2542
Gender
Male 7 (53.8 %) 5 (50.0 %) 7 (70.0 %) 14 (77.8 %) 7 (70.0 %) 0.5205
Female 6 (46.2 %) 5 (50.0 %) 3 (30.0 %) 4 (22.2 %) 3 (30.0 %)
Ethnicity
Hispanic 3 (23.1 %) 3 (30.0 %) 1 (10.0 %) 1 (5.6 %) 1 (10.0 %) 0.3881
Non-Hispanic 10 (76.9 %) 7 (70.0 %) 9 (90.0 %) 17 (94.4 %) 9 (90.0 %)
Race
White 9 (69.2 %) 7 (70.0 %) 7 (70.0 %) 12 (66.7 %) 8 (80.0 %) 0.9660
Black or African American 4 (30.8 %) 3 (30.0 %) 3 (30.0 %) 6 (33.3 %) 2 (20.0 %)
Mean baseline SBP (SD), mmHg 151 (16.7) 152 (14.1) 143 (12.0) 150 (12.9) 155 (17.1) 0.4725
Mean baseline DBP (SD), mmHg 84 (4.1) 79 (10.1) 87 (15.8) 86 (12.9) 89 (7.7) 0.3760
Mean baseline HR (SD), bpm 66 (11.0) 64 (12.3) 82 (8.1) 67 (10.8) 73 (13.6) 0.0033
Hypertension 13 (100.0 %) 10 (100.0 %) 10 (100.0 %) 18 (100.0 %) 10 (100.0 %) 1.0
Number of subjects on prior
antihypertensive medications ( %)
6 (46.2 %) 6 (60.0 %) 5 (50.0 %) 6 (33.3 %) 6 (60.0 %) 0.6029
Number of antihypertensive
medications per subject, mean (median)
1.3 (1.0) 1.2 (1.0) 1.0 (1.0) 2.2 (2.0) 1.5 (1.5)
Hospitalization for hypertension 1 (7.7 %) 0 (0.0 %) 1 (10.0 %) 0 (0.0 %) 1 (10.0 %) 0.4331
Diabetes (non-insulin-dependent) 2 (15.4 %) 3 (30.0 %) 3 (30.0 %) 3 (16.7 %) 3 (30.0 %) 0.7657
Transient ischemic attack 0 (0.0 %) 1 (10.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0.4918
Cigarette smoker 3 (23.1 %) 2 (20.0 %) 2 (20.0 %) 2 (11.1 %) 0 (0.0 %) 0.6889
COPD 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 1 (10.0 %) 0.4918
Dyslipidemia 2 (15.4 %) 5 (50.0 %) 1 (10.0 %) 3 (16.7 %) 2 (20.0 %) 0.2713
Table data expressed as number (percentage) unless otherwise noted
BMI 0 body mass index; SBP 0 systolic blood pressure; DBP 0 diastolic blood pressure; HR 0 heart rate; SD 0 standard deviation; COPD 0
chronic obstructive pulmonary disease
P values for screening demographics and baseline BP and heart rate are based on one-way ANOVA (continuous variables) or Chi-squared test




























36 48 60 72
Time (hours)
Cohort 1 (2 mg/h) n=10
Cohort 2 (4 mg/h) n=10
Cohort 3 (8 mg/h) n=10
Cohort 4 (16 mg/h) n=10
Placebo n=13
Fig. 1 Mean percentage change from baseline in systolic blood pressure
versus time over the full study drug infusion period for all clevidipine
dosing cohorts (per-protocol population). SBP systolic blood pressure
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evidence of rebound (Fig. 2a). A rapid onset of DBP reduction,
rapid return to baseline DBP, and no rebound in DBPwere also
shown in all dose cohorts.
A post-hoc analysis of mean percentage change from base-
line in SBP for up to 8 h after the end of infusion was
performed, with integration of additional BP safety monitoring
assessments at 6 and 8 h. To avoid confounding the analysis,
subjects were excluded if they restarted their oral antihyper-
tensive therapy within 4 to 8 h after the end of infusion. There
were nonsignificant trends toward higher than baseline blood
pressures at 8 h (but not at 6 h) in the clevidipine-treated
subjects, without an apparent dose–response relationship
(Fig. 2b): oscillations in mean percentage change in SBP from
baseline were noted from 9% below to 6 % above baseline for
8 h after infusion end for the four clevidipine dose groups.
Blood pressures in the placebo group were prominently below
baseline at 6 and 8 h with mean percentage change in SBP
remaining negative (i.e. below baseline). As a result of this
negative trend, placebo-adjusted mean percentage change in
SBP for the clevidipine dose groups shows a positive trend 6
and 8 h after cessation of clevidipine infusion (Fig. 2c). A
similar exploratory analysis (not shown) showed no evidence
of rebound in DBP for the full 8 h after the end of infusion.
Pharmacokinetic evaluation
Mean clevidipine blood concentrations versus time were
variable throughout the infusion period and decreased biex-
ponentially after infusion cessation across all clevidipine
dosing cohorts (Fig. 3). Following IV infusion, there was a
less than dose-proportional increase in mean Cmax, Css, and
AUC0-t between the clevidipine 2.0 mg/h cohort and the
16.0 mg/h cohort (Table 2). For an 8-fold increase in dose,
there was an increase of approximately 4.7-fold in Cmax,
~6.7-fold in Css, and ~5.9-fold in AUC0-t. Consequently, a
decrease in dose-normalized Cmax and a decrease in dose-
normalized AUC0-t were observed, as dose increased. Mean
t½ ranged from 3 to 4 min in the initial decline phase and
from 32 to 37 min in the later terminal phase, across all dose
groups (Table 2). The calculated mean clearance for clevi-
dipine was approximately 30 L/min, and was similar across
all dose groups evaluated (Table 2).
Pharmacodynamic and pharmacokinetic relationship
The individual Css values across cohorts were evaluated versus
the respective matching percentage change from baseline SBP
values. Although variability was observed, there was a visual
trend toward a greater percentage decrease in SBP from base-
line with increased steady-state blood concentrations of clevi-
dipine (Fig. 4). The concentration–response curve was shallow
and there was no apparent maximal response in change from
baseline SBP over the range of Css values evaluated.
A random coefficient regression model (Fig. 5) was used to
estimate the dose–response relationship between percentage
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Fig. 2 Mean percentage change from baseline in systolic blood pres-
sure versus time after the end of study drug infusion (per-protocol
population). a 0–4 h post-infusion. b 0–8 h post-infusion, excluding
subjects who took oral antihypertensive medications within 8 h. c 0–
8 h post-infusion (excluding subjects who took oral antihypertensive
medications within 8 h) and adjusted for placebo response
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(mg/h). Themaximum percentage change from baseline in SBP
predicted by the model (Table 3) was associated with a clevidi-
pine infusion rate of 16mg/h andwas estimated at −22% (lower
limit of 95% confidence interval [CI] −22.32%, −9.53%; point
estimate: −15.93 %). An estimated clevidipine infusion rate of
approximately 10 mg/h was needed to achieve half this rate.
Fig. 3 Mean clevidipine blood
concentrations versus time







Css (ng/mL) CL (L/min) t½ (earlier phase; min) t½ (later phase; min)
2 10 3.36 (1.35) 122 (56) 1.37 (0.70) 33.2 (21.0) 4.18 (2.59)a NC
4 10 5.17 (1.67) 211 (92) 3.00 (1.25) 26.1 (10.9) 3.28 (1.06)a 37.0 (29.9)b
8 10 7.68 (2.37) 327 (109) 5.12 (1.62) 28.5 (9.91) 3.16 (1.40) 32.4 (33.6)a
16 10 15.8 (4.01) 724 (246) 9.20 (3.37) 33.4 (14.7) 3.34 (0.96) 37.3 (21.7)c
Data expressed as mean (SD)
NC 0 Not calculated; AUC0-t 0 area under the concentration–time curve from time zero to the last quantifiable concentration; Cmax 0 maximum
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Based on the ITT population, the maximum percentage
change from baseline was estimated at −25 % (lower limit of
95 % CI of −24.15 %, −9.39 %; point estimate: −16.77 %).
Table 3 also predicts that every 1 mg/h increase in the clevi-
dipine infusion rate was associated with a 1 % to 1.5 %
decrease in SBP. That is, given a mean baseline SBP of
150 mmHg, an increase of approximately 1–2 mg/h in the
infusion rate of clevidipine may produce an additional 2–
4 mmHg decrease in SBP from baseline.
Tolerance
To evaluate the potential for subjects to develop acute toler-
ance to prolonged infusions of clevidipine, plots of individual
clevidipine blood concentration versus percentage change
from baseline SBP during the 72-h drug infusion, and up to
1 h post-drug infusion were generated for the clevidipine
16.0 mg/h cohort. Based on visual inference, there was no
evidence of hysteresis (different percentage change in SBP
from baseline at the same clevidipine concentration during
infusion or washout) and thus no evidence of acute tolerance
during the observation period. The change from baseline SBP
remained relatively constant during the infusion period, and a
trend toward increasing change from baseline SBP with in-
creased clevidipine concentration was observed, providing
further evidence that tolerance does not occur over a 72-
h clevidipine infusion.
Safety
All subjects received clevidipine or placebo as a 72-h IV
infusion with the exception of one subject who withdrew from
the study. Forty-eight subjects comprised the safety popula-
tion and received total clevidipine doses between 144 mg and
1,152.7 mg. Safety assessments based on clinical laboratory
test results were similar among all dose groups. There were no
treatment- or dose-related trends in the blood chemistry or
hematology results during the study. One subject receiving
clevidipine 8.0 mg/h had an alanine aminotransferase (ALT)
level of 55 U/L (standard normal range 13 to 40 U/L) on Day
7. Nine clevidipine-treated subjects had one or more post-
baseline triglyceride levels greater than 500 mg/dL (of poten-
tial clinical significance); 2 of these subjects had elevated
triglycerides at baseline. Of the remaining 7 subjects, 1
(8.0 mg/h cohort) had triglyceride levels >500 mg/dL on
Day 4, and 6 subjects had elevated triglycerides on Days 7/
8, but not at 0 to 8 h post-cessation of clevidipine infusion. No
changes or findings associated with study drug safety were
noted from the 12-lead ECGs for this study.
Forty-three out of 61 subjects experienced one or more
AEs, generating a total of 112 reported AEs (Table 4). The
majority were assessed as mild or moderate and 1 (back pain
in a placebo-treated subject) was assessed as severe. The
number of AEs and subjects reporting AEs were similar
across treatment groups. The most commonly reported
treatment-emergent AEs were headache, infusion site reac-
tion, and infusion site swelling (Table 5).
No deaths or serious AEs occurred during this study. One
subject treated with clevidipine (8.0 mg/h) withdrew from the
study after experiencing three AEs (generalized facial pres-
sure, headache, and nausea) that were assessed as mild and
treatment-related. The AEs were reported and resolved on
Day 1, and the subject withdrew from the study on Day 2.
Table 3 Prediction of
dose response (per
protocol population)
Infusion rate Prediction of % change
in SBP (95 % CI)
2 mg/h 0.83 (−1.16, 2.82)
4 mg/h −3.99 (−6.29, −1.69)
8 mg/h −11.20 (−14.61, −7.80)
10 mg/h −13.59 (−17.23, −9.95)
16 mg/h −15.93 (−22.32, −9.53)
Fig. 4 Clevidipine Css versus mean percentage change from baseline
in systolic blood pressure at steady state, pooled across all cohorts
Fig. 5 Model* prediction of systolic blood pressure dose–response
(per protocol population)
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Discussion
The results of this study support the use of IV clevidipine in
BP management for up to 72 h. In subjects with mild to
moderate essential hypertension, 72-h continuous infusion
did not affect the PK or PD characteristics of clevidipine over
the dose range of 2.0 to 16.0mg/h. No evidence of tolerance to
the drug effect over a 72-h infusion, or of rebound hyperten-
sion for 4 or 6 h after termination of infusion was observed.
Furthermore, no hysteresis was seen after examining each
individual plot of clevidipine concentrations versus change
from baseline in SBP for the high-dose cohort (16.0 mg/h),
indicating that acute tolerance did not occur during a 72-
h infusion. Clevidipine demonstrated a favorable safety and
tolerability profile when administered as a prolonged contin-
uous IV infusion.
Previous studies of clevidipine infusions over shorter dura-
tions have demonstrated a linear relationship between blood
concentrations at steady-state and dose rate [14, 15]. Based on
post-hoc analysis with a random coefficient regression model,
the maximal effect of clevidipine in blood pressure reduction
was estimated at 25 % of baseline SBP at 16 mg/h, and the
estimated infusion rate needed to achieve half this maximal
effect was estimated to be approximately 10 mg/h.
The elimination half-lives of clevidipine observed after 72 h
are similar to those obtained after a 20-min infusion in healthy
volunteers at a final dose rate of 3.2 μg/min/kg (approximately
16 mg/h), reported as 0.6 and 2.3 min for the initial two rapid
elimination phases (accounting for about 95 % of the area
under the concentration–time curve) and 16 min for the
terminal phase [8–10]. In the present study, because no blood
samples were obtained within the first 2 min after infusion
cessation, the t½ values assessed for the 16mg/h dosing cohort
probably represent the second and terminal decline phases of
the clevidipine blood concentration time profile. The clear-
ance of clevidipine was very high and similar across all dose
groups evaluated. The clearance is much greater than cardiac
output and is a consequence of the rapid and complete metab-
olism that occurs within a short time of administration.
Clevidipine is metabolized through hydrolysis of the ester
linkage by esterases in the blood and extravascular tissues to
inactive metabolites, accounting for its ultra-short elimination
half-life [16, 17]. Rapid clearance from the blood and a lack of
accumulation in tissues suggest that clevidipine is unlikely to
exert long-term effects after the infusion is stopped, such as
the minimal elevations in serum potassium and ALTobserved
4 days after discontinuation of infusion in the present study.
The lack of a known mechanism also makes it less plausi-
ble that a true rebound effect would be observed 8 h after
stopping infusion, given that no evidence of rebound hyper-
tension is observed 6 h after infusion cessation and no clear
dose–response relationship at 8 h can be determined. In this
study, the placebo group showed a negative mean percentage
change in SBP after stopping the infusion. No specific reason
for this observation is known, although untreated SBP may be
expected to fluctuate in both directions, and a placebo effect
resulting in sustained SBP reduction in subjects with acute
hypertension has been observed in previous studies [6, 7]. The
observedmean reduction was primarily driven by two placebo
patients having large SBP reductions, and may simply have
been due to reduced anxiety as they completed their last study
SBP assessments. A post-hoc comparison of SBPs for subjects
receiving prior antihypertensive medication with those not
having prior medication confirmed that there were no mean-
ingful differences in these subpopulations during study drug
infusion and following termination of study drug infusion. The
larger percentage decrease in SBP from baseline with the
2.0 mg/h cohort than with the 4.0 mg/h cohort may possibly
be related to the lower baseline SBP in the 4.0 mg/h cohort
(143 mmHg vs 152 mmHg for the 2.0 mg/h cohort).
Table 4 Adverse events
by treatment group
(safety population)
Adverse Events Clevidipine N048 Placebo Total
2 mg/h 4 mg/h 8 mg/h 16 mg/h
n010 n010 n018 n010 n013 n061
Number of adverse events 20 15 23 26 28 112
Number of subjects with AEs ( %) 9 (90) 7 (70) 12 (67) 8 (80) 7 (54) 43 (70)
Severity, number of subjects ( %)
Mild 8 (80) 5 (50) 12 (67) 8 (80) 7 (54) 40 (66)
Moderate 3 (30) 5 (50) 1 (6) 1 (10) 2 (15) 12 (20)
Severe 0 0 0 0 1 (8) 1 (2)
Table 5 Most common treatment-emergent adverse events (TEAEs;
safety population)
Most common TEAEs Clevidipine N048 Placebo N013
n ( %) n ( %)
Headache 18 (37.5) 2 (15.4)
Infusion site reaction 6 (12.5) 4 (30.8)
Infusion site swelling 5 (10.4) 1 (7.7)
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Of the 9 subjects who had one or more post-baseline
normalized triglycerides that were greater than 500 mg/dL, 6
subjects had potentially clinically significant elevations on
Days 7 and 8. These elevations were not thought to be caused
by clevidipine administration as the infusion had ended 3 or
4 days prior to the collection of blood samples for clinical
chemistry evaluation. Two of the remaining subjects had
elevated triglycerides at baseline, one of whom was shown
to have dyslipidemia prior to entering the study. The one
subject with elevated triglyceride levels on Day 4 was receiv-
ing clevidipine infusion at the same time that the blood sample
was drawn. Since clevidipine emulsion and Intralipid® contain
20 % soybean oil (composed primarily of triglycerides), this
finding is understandable. Overall, the changes in triglycerides
were sporadic, not dose dependent, and, in the majority of
subjects, not thought to be drug related. In previous clinical
studies with clevidipine emulsion, there were no reports of
adverse clinical effects due to the Intralipid® formulation.
However, patients with disorders of lipid metabolism may
be less able to rapidly clear fat from circulation, thereby
resulting in transient triglyceride elevations.
After 72-h continuous infusion with IV clevidipine 2.0 to
16.0 mg/h in subjects with mild to moderate essential hyper-
tension, no tolerance to drug effects over a 72-h continuous
infusion, and no rebound hypertension for up to 6 h after
infusion cessationwas observed over all clevidipine dose levels.
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